306 related articles for article (PubMed ID: 27125895)
1. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
Gao M; Ma Y; Alsaggar M; Liu D
AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
[TBL] [Abstract][Full Text] [Related]
2. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-
Liu Y; Cheng F; Luo Y; Zhan Z; Hu P; Ren H; Tang H; Peng M
Biomed Res Int; 2017; 2017():8234507. PubMed ID: 28770225
[TBL] [Abstract][Full Text] [Related]
3. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Schmilovitz-Weiss H; Hochhauser E; Cohen M; Chepurko Y; Yitzhaki S; Grossman E; Leibowitz A; Ackerman Z; Ben-Ari Z
Lipids Health Dis; 2013 Mar; 12():41. PubMed ID: 23531105
[TBL] [Abstract][Full Text] [Related]
5. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet.
Zheng F; Cai Y
Lipids Health Dis; 2019 Jan; 18(1):6. PubMed ID: 30611282
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
Lee SM; Muratalla J; Diaz-Ruiz A; Remon-Ruiz P; McCann M; Liew CW; Kineman RD; Cordoba-Chacon J
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34417811
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.
Minge CE; Bennett BD; Norman RJ; Robker RL
Endocrinology; 2008 May; 149(5):2646-56. PubMed ID: 18276752
[TBL] [Abstract][Full Text] [Related]
9. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.
Sun X; Tang Y; Tan X; Li Q; Zhong W; Sun X; Jia W; McClain CJ; Zhou Z
Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G548-57. PubMed ID: 22173916
[TBL] [Abstract][Full Text] [Related]
10. Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
Hemmeryckx B; Gaekens M; Gallacher DJ; Lu HR; Lijnen HR
Basic Clin Pharmacol Toxicol; 2013 Nov; 113(5):353-60. PubMed ID: 23789962
[TBL] [Abstract][Full Text] [Related]
11. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Lu M; Sarruf DA; Talukdar S; Sharma S; Li P; Bandyopadhyay G; Nalbandian S; Fan W; Gayen JR; Mahata SK; Webster NJ; Schwartz MW; Olefsky JM
Nat Med; 2011 May; 17(5):618-22. PubMed ID: 21532596
[TBL] [Abstract][Full Text] [Related]
12. Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet.
Xia SF; Le GW; Wang P; Qiu YY; Jiang YY; Tang X
Nutrients; 2016 Dec; 8(12):. PubMed ID: 27973423
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
15. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I
Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
[TBL] [Abstract][Full Text] [Related]
17. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease.
Luo W; Xu Q; Wang Q; Wu H; Hua J
Sci Rep; 2017 Mar; 7():44612. PubMed ID: 28300213
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Gupte AA; Liu JZ; Ren Y; Minze LJ; Wiles JR; Collins AR; Lyon CJ; Pratico D; Finegold MJ; Wong ST; Webb P; Baxter JD; Moore DD; Hsueh WA
Hepatology; 2010 Dec; 52(6):2001-11. PubMed ID: 20938947
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
20. Palmitoleic acid reduces high fat diet-induced liver inflammation by promoting PPAR-γ-independent M2a polarization of myeloid cells.
Souza CO; Teixeira AAS; Biondo LA; Silveira LS; de Souza Breda CN; Braga TT; Camara NOS; Belchior T; Festuccia WT; Diniz TA; Ferreira GM; Hirata MH; Chaves-Filho AB; Yoshinaga MY; Miyamoto S; Calder PC; Sethi JK; Rosa Neto JC
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158776. PubMed ID: 32738301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
